Overall rank by patents
#5,252
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Takeda Vaccines, Inc.
USPTO PatentsView assignee record - 66 granted patents across 10 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
66
Total patents granted
10
CPC technology areas
22.9
Avg claims per patent
+6%
5-year filing velocity
The verdict
Takeda holds 66 US patents across 10 technology areas, rank #5,252 of 50,000 tracked assignees.
- #5,252
- of 50,000 US assignees by volume
- Top 24%
- by Innovation Score (45.1/100)
- 22.9
- avg claims per patent
- +6%
- filing velocity, last 5 yrs
Portfolio overview
Takeda Vaccines, Inc. has been granted 66 US utility patents between 2015 and 2025, placing Takeda Vaccines, Inc. at rank #5,252 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.9 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Takeda Vaccines, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Takeda sits between Superior Industries, Inc. (66 patents, rank #5,248) and Urschel Laboratories, Inc. (66 patents, rank #5,256) - the closest US assignees by grant volume. The composite Innovation Score of 45.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 34 grants, compared with 32 in the 2015–2019 window, a +6% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Takeda Vaccines, Inc.'s 22.9 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Takeda Vaccines, Inc. against peers pursuing similar technology classes.
Who files at Takeda's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Superior Industri…
Superior Industries, Inc.
66 patents
- Tekelec
TEKELEC, INC.
66 patents
- TPK Advanced Solu…
TPK Advanced Solutions Inc.
66 patents
- TREK Bicycle
TREK BICYCLE CORPORATION
66 patents
- Theranos IP
Theranos IP Company, LLC
66 patents
- Toast
Toast, Inc.
66 patents
- University of Pue…
University of Puerto Rico
66 patents
- Urschel Laborator…
Urschel Laboratories, Inc.
66 patents
- Takeda Vaccines ◀
Takeda Vaccines, Inc.
66 patents
What this shows Takeda holds 66 patents at rank #5,252, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Takeda
By rank, the assignees closest to #5,252 in granted patent volume.
- Superior Industries, Inc. #5,248 · 66 patents
- Tekelec, Inc. #5,249 · 66 patents
- TPK Advanced Solutions Inc. #5,250 · 66 patents
- TREK Bicycle Corporation #5,251 · 66 patents
- Theranos IP Company, Llc #5,253 · 66 patents
- Toast, Inc. #5,254 · 66 patents
- University Of Puerto Rico #5,255 · 66 patents
- Urschel Laboratories, Inc. #5,256 · 66 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Takeda's primary technology class.
- Monsanto Technology Llc 1,335 in class
- The Regents Of The University Of California 1,161 in class
- Novozymes A/s 656 in class
- Immatics Biotechnologies Gmbh 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President And Fellows Of Harvard College 594 in class
- Massachusetts Institute Of Technology 541 in class
- The Trustees Of The University Of Pennsylvania 537 in class
Takeda's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
45 Top 24% higher than 76% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 6 | 9.1% |
| 2016 | 6 | 9.1% |
| 2017 | 5 | 7.6% |
| 2018 | 9 | 13.6% |
| 2019 | 6 | 9.1% |
| 2020 | 8 | 12.1% |
| 2021 | 6 | 9.1% |
| 2022 | 4 | 6.1% |
| 2023 | 6 | 9.1% |
| 2024 | 7 | 10.6% |
| 2025 | 3 | 4.5% |
Which technologies does Takeda Vaccines, Inc. patent most?
Top 10 of 10 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Growing
Frequently Asked Questions
How many patents does Takeda Vaccines, Inc. hold?
Takeda Vaccines, Inc. holds 66 US granted patents filed between 2015 and 2025, spanning 10 technology areas.
What is Takeda Vaccines, Inc.'s Innovation Score?
Takeda Vaccines, Inc. has an Innovation Score of 45.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Takeda Vaccines, Inc. focus on?
Takeda Vaccines, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 65 patents. The company has filed patents in 10 CPC subclasses total.
Is Takeda Vaccines, Inc.'s patent filing rate increasing or decreasing?
Takeda Vaccines, Inc.'s recent filing velocity is +6% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Takeda Vaccines, Inc.'s patents?
Takeda Vaccines, Inc.'s patents average 22.9 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Takeda Vaccines, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Takeda's 66 grants land it in the top 24% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Takeda ranks #5,252 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.